Mobile

A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in pat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016468-35

A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the efficacy of cediranib when added to cisplatin plus a fluoropyrimidine compared to cisplatin plus a fluoropyrimidine alone by assessment of overall survival (OS).

Critère d'inclusion

  • Gastric Cancer

Liens